BioCentury
ARTICLE | Finance

Diversifying CureVac

How RNA play CureVac aims to diversify shareholders to attract U.S. investors

November 18, 2016 6:21 PM UTC

CureVac AG’s most recent financing is another step toward diversifying the RNA company’s shareholder base to make it more attractive to U.S. investors.

On Nov. 8, CureVac raised $29.5 million in the second tranche of a private financing led by two new generalist German investors: Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte; and Landeskreditbank Baden-Württemberg...